This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.
Johnson &Johnson's IL-12/IL-23 blocker Stelara (ustekinumab) was the first interleukin drug to reach the market and swiftly reached blockbuster sales level, and has since been joined by
AbbVie reports more solid data for would-be psoriasis blockbuster. Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara. ... A pair of phase III trials pitting risankizumab against Johnson &Johnson’s older
therapy. The drug is a follow-up for its IL-23/IL-12 inhibitor Stelara, which is facing competition from newer psoriasis drugs showing greater efficacies in clinical trials.
Competes against blockbusters Stelara and Humira. AbbVie has posted a trio of positive phase III trials for its interleukin-23 inhibitor risankizumab, setting up regulatory applications but also a tough entry ... The anti-interleukin-23 (IL-23) antibody
compared to 19-22% on Johnson &Johnson’s Stelara (ustekinumab).
trials - Stelara still grew more than 22% to $983m in the second quarter. ... The company reckons Tremfya combines good efficacy with "Stelara-like safety" and a less intensive dosing regimen that will stand it in good stead in the market.
More from news
Approximately 14 fully matching, plus 55 partially matching documents found.
Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...